Movano Health has received FDA 510(k) clearance for the pulse oximeter in its EvieMED Ring, marking a pivotal achievement in its mission to deliver clinical-grade health monitoring solutions. Originally launched in the consumer wearable market, the EvieMED Ring is now positioned to expand into B2B healthcare applications, including clinical trials, remote patient monitoring, and post-trial management. The device provides accurate blood oxygen (SpO2) and heart rate measurements with enhanced comfort and compliance, addressing the limitations of traditional pulse oximeters. Its innovative design features a flexible gap for finger swelling, enabling continuous wear and reliable data collection.
Since its founding in 2018, Movano Health has focused on creating medical-grade wearable devices that prioritize both comfort and accuracy. In addition to measuring SpO2 and heart rate, the EvieMED Ring tracks other key health metrics such as sleep, activity, respiration rate, and temperature variability, offering a more comprehensive view of a user’s health. The company is also exploring the potential of its proprietary RF technology to support future advancements in cuffless blood pressure and noninvasive glucose monitoring, further enhancing its healthcare offerings.
